{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:10:44Z","timestamp":1778692244895,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grants-in-Aid from the Ministry of Education for Science and Culture of Japan","award":["26462408"],"award-info":[{"award-number":["26462408"]}]},{"name":"Grants-in-Aid from the Ministry of Education for Science and Culture of Japan","award":["16K11000"],"award-info":[{"award-number":["16K11000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00432-017-2536-x","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T23:48:59Z","timestamp":1509580139000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells"],"prefix":"10.1007","volume":"144","author":[{"given":"Kenichiro","family":"Ishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminobu","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-9246","authenticated-orcid":false,"given":"Yoshiki","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"2536_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1464-410X.2012.11667.x","volume":"111","author":"WL Dahut","year":"2013","unstructured":"Dahut WL et al (2013) Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int 111:1269\u20131280. \n                        https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11667.x","journal-title":"BJU Int"},{"key":"2536_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/1476-4598-9-301","volume":"9","author":"M Bruyn de","year":"2010","unstructured":"de Bruyn M et al (2010) Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 9:301. \n                        https:\/\/doi.org\/10.1186\/1476-4598-9-301","journal-title":"Mol Cancer"},{"key":"2536_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/annonc\/mdp111","volume":"20","author":"M Dror Michaelson","year":"2009","unstructured":"Dror Michaelson M et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913\u2013920. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdp111","journal-title":"Ann Oncol"},{"key":"2536_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1677\/ERC-08-0130","volume":"16","author":"C Festuccia","year":"2009","unstructured":"Festuccia C et al (2009) Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 16:401\u2013413. \n                        https:\/\/doi.org\/10.1677\/ERC-08-0130","journal-title":"Endocr Relat Cancer"},{"key":"2536_CR5","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","volume":"31","author":"K Fizazi","year":"2013","unstructured":"Fizazi K et al (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740\u20131747. \n                        https:\/\/doi.org\/10.1200\/JCO.2012.46.4149","journal-title":"J Clin Oncol"},{"key":"2536_CR6","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.juro.2007.06.043","volume":"178","author":"AM Harris","year":"2007","unstructured":"Harris AM et al (2007) Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178:2176\u20132180. \n                        https:\/\/doi.org\/10.1016\/j.juro.2007.06.043","journal-title":"J Urol"},{"key":"2536_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/annonc\/mds505","volume":"24","author":"A Heidenreich","year":"2013","unstructured":"Heidenreich A et al (2013) A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human alphanu integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol 24:329\u2013336. \n                        https:\/\/doi.org\/10.1093\/annonc\/mds505","journal-title":"Ann Oncol"},{"key":"2536_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1940-6207.CAPR-10-0189","volume":"4","author":"Y Hori","year":"2011","unstructured":"Hori Y et al (2011) Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 4:87\u201396. \n                        https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0189","journal-title":"Cancer Prev Res (Phila)"},{"key":"2536_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12154-014-0122-0","volume":"8","author":"K Ishii","year":"2015","unstructured":"Ishii K, Sugimura Y (2015) Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug J. Chem Biol 8:5\u20139. \n                        https:\/\/doi.org\/10.1007\/s12154-014-0122-0","journal-title":"Chem Biol"},{"key":"2536_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/1940-6207.CAPR-13-0095","volume":"6","author":"Y Iwamoto","year":"2013","unstructured":"Iwamoto Y et al (2013) Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells. Cancer Prev Res (Phila) 6:1000\u20131006. \n                        https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0095","journal-title":"Cancer Prev Res (Phila)"},{"key":"2536_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2367-9","author":"Y Iwamoto","year":"2017","unstructured":"Iwamoto Y et al (2017) Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. J Cancer Res Clin Oncol. \n                        https:\/\/doi.org\/10.1007\/s00432-017-2367-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"2536_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/pros.20975","volume":"69","author":"K Izumi","year":"2009","unstructured":"Izumi K et al (2009) Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate 69:1222\u20131234. \n                        https:\/\/doi.org\/10.1002\/pros.20975","journal-title":"Prostate"},{"key":"2536_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/381643a0","volume":"381","author":"T Jacks","year":"1996","unstructured":"Jacks T, Weinberg RA (1996) Cell-cycle control and its watchman. Nature 381:643\u2013644. \n                        https:\/\/doi.org\/10.1038\/381643a0","journal-title":"Nature"},{"key":"2536_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253\u2013265. \n                        https:\/\/doi.org\/10.1038\/nrc1317","journal-title":"Nat Rev Cancer"},{"key":"2536_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ijc.23095","volume":"122","author":"H Kanda","year":"2008","unstructured":"Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y (2008) Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 122:444\u2013451. \n                        https:\/\/doi.org\/10.1002\/ijc.23095","journal-title":"Int J Cancer"},{"key":"2536_CR16","doi-asserted-by":"crossref","unstructured":"Kawabe K (2006) [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia] Yakugaku Zasshi 126 Spec no., pp 199\u2013206","DOI":"10.1248\/yakushi.126.199"},{"key":"2536_CR17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/annonc\/mdp524","volume":"21","author":"M Khasraw","year":"2010","unstructured":"Khasraw M et al (2010) Multicentre phase I\/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 21:1302\u20131307. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdp524","journal-title":"Ann Oncol"},{"key":"2536_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s10147-012-0463-z","volume":"18","author":"T Kuramoto","year":"2013","unstructured":"Kuramoto T et al (2013) Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer. Int J Clin Oncol 18:890\u2013897. \n                        https:\/\/doi.org\/10.1007\/s10147-012-0463-z","journal-title":"Int J Clin Oncol"},{"key":"2536_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1535-7163.MCT-04-0244","volume":"4","author":"Y Li","year":"2005","unstructured":"Li Y, Hong X, Hussain M, Sarkar SH, Li R, Sarkar FH (2005) Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 4:389\u2013398. \n                        https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0244","journal-title":"Mol Cancer Ther"},{"key":"2536_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ncpuro0099","volume":"2","author":"NJ Mackler","year":"2005","unstructured":"Mackler NJ, Pienta KJ (2005) Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2:92\u2013100. \n                        https:\/\/doi.org\/10.1038\/ncpuro0099\n                        \n                     (quiz 101 p following 112)","journal-title":"Nat Clin Pract Urol"},{"key":"2536_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","volume":"6","author":"A Montero","year":"2005","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229\u2013239. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(05)70094-2","journal-title":"Lancet Oncol"},{"key":"2536_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bjc.6605188","volume":"101","author":"TJ Murtola","year":"2009","unstructured":"Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A (2009) Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 101:843\u2013848. \n                        https:\/\/doi.org\/10.1038\/sj.bjc.6605188","journal-title":"Br J Cancer"},{"key":"2536_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10147-013-0536-7","volume":"19","author":"Y Nakai","year":"2014","unstructured":"Nakai Y et al (2014) Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol 19:165\u2013172. \n                        https:\/\/doi.org\/10.1007\/s10147-013-0536-7","journal-title":"Int J Clin Oncol"},{"key":"2536_CR24","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","volume":"28","author":"YM Ning","year":"2010","unstructured":"Ning YM et al (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:2070\u20132076. \n                        https:\/\/doi.org\/10.1200\/JCO.2009.25.4524","journal-title":"J Clin Oncol"},{"key":"2536_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.ju.0000097026.43866.cc","volume":"171","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG, Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029\u20131035. \n                        https:\/\/doi.org\/10.1097\/01.ju.0000097026.43866.cc","journal-title":"J Urol"},{"key":"2536_CR26","doi-asserted-by":"publisher","unstructured":"Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R (2017) Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53\/p21WAF1\/CIP1 and p27KIP1 pathway. Oncotarget. \n                        10.18632\/oncotarget.15303","DOI":"10.18632\/oncotarget.15303"},{"key":"2536_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","volume":"23","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G et al (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23:1803\u20131808. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdr555","journal-title":"Ann Oncol"},{"key":"2536_CR28","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","volume":"20","author":"CN Sternberg","year":"2009","unstructured":"Sternberg CN et al (2009) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20:1264\u20131269. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdn784","journal-title":"Ann Oncol"},{"key":"2536_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000315994","volume":"85","author":"S Tsuritani","year":"2010","unstructured":"Tsuritani S, Nozaki T, Okumura A, Kimura H, Kazama T (2010) A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75\u00a0mg once daily in the evening compared to 25\u00a0mg thrice daily. Urol Int 85:80\u201387. \n                        https:\/\/doi.org\/10.1159\/000315994","journal-title":"Urol Int"},{"key":"2536_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.juro.2009.02.105","volume":"182","author":"UN Vaishampayan","year":"2009","unstructured":"Vaishampayan UN et al (2009) Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 182:317\u2013323. \n                        https:\/\/doi.org\/10.1016\/j.juro.2009.02.105","journal-title":"J Urol"},{"key":"2536_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/iju.12156","volume":"20","author":"D Yamada","year":"2013","unstructured":"Yamada D et al (2013) Reduction of prostate cancer incidence by naftopidil, an alpha1 -adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor. Int J Urol 20:1220\u20131227. \n                        https:\/\/doi.org\/10.1111\/iju.12156","journal-title":"Int J Urol"},{"key":"2536_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/j.1442-2042.2006.01443.x","volume":"13","author":"T Yokoyama","year":"2006","unstructured":"Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T (2006) Comparison of 25 and 75\u00a0mg\/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 13:932\u2013938. \n                        https:\/\/doi.org\/10.1111\/j.1442-2042.2006.01443.x","journal-title":"Int J Urol"},{"key":"2536_CR33","first-page":"2096","volume":"63","author":"H Yonou","year":"2003","unstructured":"Yonou H et al (2003) Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice. Cancer Res 63:2096\u20132102","journal-title":"Cancer Res"},{"key":"2536_CR34","doi-asserted-by":"publisher","first-page":"e91817","DOI":"10.1371\/journal.pone.0091817","volume":"9","author":"S Zhu","year":"2014","unstructured":"Zhu S, Oremo JA, Li S, Zhen M, Tang Y, Du Y (2014) Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer. PLoS One 9:e91817. \n                        https:\/\/doi.org\/10.1371\/journal.pone.0091817","journal-title":"PLoS One"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2536-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T03:26:00Z","timestamp":1515209160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2536"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2536-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}